S
urgical-site infection is a potential complication for all surgical procedures and is one of the leading causes of morbidity for postmastectomy breast reconstruction. [1] [2] [3] Surgical-site infections have been reported in approximately 2 percent of patients undergoing postmastectomy implant breast reconstruction. 2 Although this rate has varied widely in a number of different studies, 4 it likely represents infections that required implant removal. Infections can range from mild cellulitis requiring oral antibiotics to more severe cellulitis resolving with inpatient intravenous antibiotics to frank abscess formation requiring implant removal, and thus the actual rates of infection, if defined more broadly, may be much higher.
Most plastic surgeons prescribe preoperative prophylactic antibiotics for patients undergoing breast reconstruction and continue perioperative prophylactic antibiotics administered intravenously during hospitalization and orally on discharge until a set time (e.g., 7 days) or until drains are removed. 5 This practice has been prone to criticism by infection control officers and others who quote data from studies 6 -11 suggesting that, despite the increasing use of prophylactic antibiotics, there has been no corresponding decrease in rates of infection postoperatively. However, Hawn and colleagues 12 recently examined the efficacy of improved adherence to the Surgical Care Improvement Project guidelines and noted stable rates of surgical-site infection at the patient and hospital levels despite increased use of preoperative prophylactic antibiotics and decreased use of postoperative prophylactic antibiotics. These studies would suggest that prolonged (Ͼ24 hours) postoperative prophylactic antibiotics are not indicated for routine clean surgical procedures.
At our university-affiliated tertiary care center, guidelines governing the use of perioperative antibiotic prophylaxis were implemented in October of 2008 based on pay-for-performance incentives and the Surgical Care Improvement Project. Our Division made a decision to adopt evidence-based perioperative antibiotic prophylaxis guidelines and in January of 2009 began prescribing a single preoperative dose for all patients undergoing breast reconstruction. Patients undergoing lengthy operations (e.g., perforator flap) were given additional intraoperative doses as indicated. Although the Surgical Care Improvement Project protocol permitted up to 24 hours of postoperative antibiotics, our group made a decision not to give any postoperative prophylactic antibiotics in an effort to engage in strictly evidence-based medicine.
In the ensuing year, an increase in the rate of postoperative surgical-site infection was noted in patients undergoing breast reconstruction, particularly those undergoing prosthetic reconstruction. This prompted a review of our experience before and after the Surgical Care Improvement Project protocol was instituted to determine whether or not the change in perioperative antibiotic prophylaxis regimen was associated with an increased risk of surgical-site infection. We hypothesized that patients receiving postoperative prophylactic antibiotics would have decreased postoperative infection rates compared with patients who received only perioperative antibiotics according to the Surgical Care Improvement Project protocol.
PATIENTS AND METHODS
This institutional review board-approved, retrospective cohort study was conducted at a tertiary academic medical center between October of 2007 and January of 2010. Patients who underwent postmastectomy breast reconstruction before implementation of the Surgical Care Improvement Project protocol between October of 2007 and October of 2008 received both preoperative and postoperative antibiotics (until drains were removed). This group was compared with similar patients who underwent postmastectomy implant or autologous reconstructions performed between January of 2009 and January of 2010. These patients received only preoperative and possibly intraoperative antibiotics in accordance with the Surgical Care Improvement Project guidelines. We report the rates of surgical-site infection in both groups using a much broader definition of infection than has been reported in the plastic surgery literature, which has tended to report only the rate of infections requiring implant removal. We categorized surgical-site infection according to the way it was treated: infections requiring oral antibiotics only, those treated with intravenous antibiotics, and those requiring reoperation.
Preoperative variables included demographic factors known to be associated with surgical-site infection, including age, body mass index, current smoking status, radiation history, chemotherapy history, tumor stage, and diabetic status. Body mass index was also categorized (Յ30 versus Ͼ30). Intraoperative variables included technical aspects of the procedure such as single or two-stage implant reconstruction and type of autologous reconstruction. Women undergoing single-stage reconstruction were excluded from all analyses. Women who received tissue expanders or permanent implants were combined for all analyses. Patients who underwent reconstruction using both an autologous flap and an implant were included in the implant group. Postoperative infection rates are reported. Povidone-iodine was the most commonly used preparation solution; however, chlorhexidine was also occasionally used. Antibiotic irrigation was used at the discretion of the attending surgeon and was not reported consistently. Non-penicillinallergic patients all received cefazolin preoperatively. Penicillin-allergic patients received either clindamycin or vancomycin; however, this information was not specifically captured in our database. After the implementation of the Surgical Care Improvement Project guidelines, we began capturing the distribution profile of organisms isolated from women who experienced postoperative infection. Bacterial isolates for women requiring removal of the implant are reported.
The majority of patients undergoing breast reconstruction had mastectomy for curative resection. Other patients underwent prophylactic mastectomy after positive genetic testing for the BRCAI and BRCAII genes or because of a strong familial history of breast cancer. In subset analyses, we also examined the use of AlloDerm (LifeCell Corp., Branchburg, N.J.) and axillary lymph node dissection, either before or concurrent with the mastectomy.
Sample Size Estimation
Although the published rate of infection after implant reconstruction is approximately 2 percent, this rate likely reflects only cases requiring removal of the implant. In a pilot study at our institution, patients undergoing implant reconstruction experienced an increase in the baseline infection rate from 5.4 percent to 18.2 percent with the implementation of the Surgical Care Improvement Project protocol. This study was adequately powered to detect a 20 percent difference in the rate of infection between the two groups studied. A type I error probability of 5 percent (alpha) and a type II error probability of 10 percent (beta) were used for this calculation. We estimated an event rate (proportion) of 10 percent in the group treated with preoperative antibiotics only. The required sample size in each of the two study groups was 47 patients, or a total sample size of 94 patients.
Statistical Analyses
Descriptive statistics, including frequencies for the independent variables and unadjusted rates of infection, are reported. Pearson's chi-square and Fisher's exact tests were used for categorical variables and t tests were used for continuous independent variables. Multivariate logistic regression using a backward, conditional modeling technique was used to investigate predictors of surgical-site infection requiring reoperation. Values of p Ͻ 0.05 were considered statistically significant. SPSS version 19 (SPSS, Inc., Chicago, Ill.) was used for all analyses.
RESULTS
A total of 250 women were included for analyses (116 in the pre-Surgical Care Improvement Project group and 134 in the Surgical Care Improvement Project group). There were no statistically significant differences in the mean age of patients, diabetic status, current smoking status, radiation history, chemotherapy history, or tumor stage between the two groups ( Table 1 ). The women in the Surgical Care Improvement Project group had a slightly higher body mass index (27.2 versus 28.8; p ϭ 0.052). The overall rate of surgical-site infection (treated with any modality) increased from 18.1 percent in the pre-Surgical Care Improvement Project group to 34.3 percent after the adoption of the Surgical Care Improvement Project treatment protocol (p ϭ 0.004) ( Table 2) . No statistically significant differences were noted in the rates of surgical-site infection successfully treated with oral or intravenous antibiotics alone, but the rate of infection requiring reoperation increased from 4.3 percent to 16.4 percent (p ϭ 0.002). Regarding the different types of reconstruction, the We also noted an increase in the number of autologous flap reconstruction surgical-site infections requiring reoperation (0 percent versus 11.4 percent); however, this difference was also not statistically significant (p ϭ 0.115).
In multivariate analyses, after adjusting for history of radiation therapy, body mass index (categorized as Յ30 versus Ͼ30), treatment group (preSurgical Care Improvement Project versus Surgical Care Improvement Project), and type of reconstruction performed (autologous versus tissue expander/ implant), patients in the Surgical Care Improvement Project group were 4.74 times (95 percent confidence interval, 1.69 to 13.80) more likely to develop a surgical-site infection requiring reoperation than patients treated in the pre-Surgical Care Improvement Project group. Furthermore, patients with a history of radiation therapy were 4.50 times (95 percent confidence interval, 1.80 to 11.29) more likely to develop a surgical-site infection requiring reoperation than patients not treated with radiation. Obese women (body mass index Ͼ30) were 4.99 times (95 percent confidence interval, 2.03 to 12.31) more likely to develop a surgical-site infection requiring reoperation, and women who underwent reconstruction with tissue expanders/implants were 3 .77 times (95 percent confidence interval, 1.11 to 12.83) more likely to develop a surgical-site infection requiring reoperation and removal of the tissue expander/implant after adjusting for the above covariates (Table 3) .
In subset analyses of the women who developed a surgical-site infection requiring reoperation (n ϭ 27), history of axillary lymph node dissection and use of AlloDerm were not associated with a surgical-site infection requiring reoperation (p ϭ 0.334 and p ϭ 0.819, respectively). Use of AlloDerm was less common (43.8 percent) in the Surgical Care Improvement Project group versus the pre-Surgical Care Improvement Project group (56.3 percent); however, the difference was not statistically significant (p ϭ 0.128). We also examined the time interval between initial surgery and the development of a surgical-site infection requiring implant removal, and compared results between the two treatment groups. We found that women in the pre-Surgical Care Improvement Project group developed a surgical-site infection a mean of 256 Ϯ 182 days after surgery compared with women in the Surgical Care Improvement Project group, who developed a surgical-site infection a mean of 90 Ϯ 93 days (p ϭ 0.011) after surgery. Regarding early infections requiring explantation (Յ30 days), fewer women in the preSurgical Care Improvement Project group (20 percent) developed such an infection compared with women in the Surgical Care Improvement Project group (35 percent) (p ϭ 0.477). Bacterial isolates before and after implementation of the Surgical Care Improvement Project guidelines are reported in Figures 1 and 2 . After implementation of the Surgical Care Improvement Project protocol, the bacterial isolates became more diverse, with a much higher incidence of Gram-negative bacteria (Fig. 2) .
DISCUSSION
Women undergo mastectomies for both prophylactic and therapeutic reasons. Whether performed to treat breast cancer or as a preventative measure for women with a genetic predisposition to cancer or strong familial indicators, breast reconstruction following a mastectomy can be performed by placement of an implant or by means of autologous techniques. Surgical-site infection following breast reconstruction can necessitate oral or intravenous antibiotic therapy, lengthen the duration of the hospital stay, or lead to loss of Plastic and Reconstructive Surgery • September 2012 the implant or flap. An evidence-based universal protocol governing the use of prophylactic antibiotics to prevent postoperative surgical-site infections following breast reconstruction does not currently exist.
1,2
The current standard of care is that a preoperative dose of prophylactic antibiotic should be given to patients undergoing postmastectomy breast reconstruction. 4, 13 In an advisory statement from the National Surgical Infection Prevention Project, which is based on published evidence, infusion of the first antimicrobial dose should begin no sooner than 60 minutes before the incision. 12 Based on published evidence, the same workgroup endorsed the national performance measure (Surgical Care Improvement Project guidelines) that prophylactic antimicrobial agents should be discontinued within 24 hours of the end of surgery. 12 However, specific recommendations for plastic surgery were not included. Many surgeons prescribe postoperative antibiotics for up to 1 week following postmastectomy breast reconstruction, whereas others routinely continue postoperative antibiotics until all drains are removed, which can be as long as 2 weeks. Volume 130, Number 3 • Antibiotics and Breast Reconstruction According to the published Guideline for Prevention of Surgical-Site Infection, 14 three categories of variables have proven to be reliable predictors of surgical-site infection risk: (1) those that estimate the intrinsic degree of microbial contamination of the surgical site, (2) those that measure the duration of an operation, and (3) those that serve as markers for host susceptibility. Patientrelated factors possibly associated with an increased risk of surgical-site infection include remote site infection or colonization, diabetes, cigarette smoking, obesity, extremes of age, and poor nutritional and immunocompromised status. [15] [16] [17] [18] [19] [20] [21] [22] Many of these characteristics are present in the plastic surgery patient population, including overweight and obese patients, current smoking status and, to a lesser extent, diabetes and immunosuppression.
There have been a number of excellent studies from the general surgery and surgical oncology literature examining surgical-site infection rates among women undergoing surgery for breast cancer. A review of this literature by Penel et al. 23 and others have documented surgical-site infection rates ranging from 1.9 to 50 percent. 24 -37 In the prospective study by Penel et al. comparing surgical-site infection rates before and after the implementation of prophylactic antibiotics, the authors conclude that the antibiotic prophylaxis reduced the risk of surgical-site infection in breast cancer surgery by 81 percent.
A recent systematic review of the literature examining preoperative and perioperative prophylactic antibiotic use in breast surgery included seven articles with a total of 1924 participants in a meta-analysis. 38 No eligible studies evaluating prophylactic antibiotics used during reconstructive surgery (with or without implants) were identified in this study. From this review, pooling of the results demonstrated that prophylactic antibiotics significantly reduce the incidence of surgical-site infection for patients undergoing breast cancer surgery without reconstruction (pooled relative risk, 0.66; 95 percent confidence interval, 0.48 to 0.89). No studies presented separate data for patients who underwent reconstructive surgery at the time of removal of the breast tumor.
Other studies have examined the overall incidence of periprosthetic infection following tissue expander insertion for breast cancer reconstruction. In a review by Francis et al., 39 the authors noted infection rates ranging from 2.5 to 24 percent. [40] [41] [42] [43] [44] [45] Other authors have reported infection rates after expander-based reconstructions ranging between 1 and 24 percent. 41 Recent findings published by the National Surgical Infection Prevention Project suggest that the administration of prophylactic antibiotics should be discontinued within 24 hours of the completion of surgery. 2 These recommendations, however, are based on studies outside of the practice of plastic surgery and are not based on studies conducted with women undergoing implant-based reconstructions. Reconstructive breast surgery differs from other types of surgery because of a greater surface area of undermined tissue, nearly universal ischemia to the skin flaps from the mastectomy, breast duct bacteria, and the possible presence of an implant.
We have noted an increase in the rate of surgical-site infections requiring treatment with oral and intravenous antibiotics and a statistically significant increase in the rate of surgical-site infection requiring reoperation since the adoption of the Surgical Care Improvement Project guidelines at our institution. Before the adoption of the Surgical Care Improvement Project guidelines, our rate of surgical-site infection requiring reoperation was similar (4.3 percent) to the rates reported in the literature (approximately 2 to 15 percent); however, we currently have an unacceptably high rate of surgical-site infection requiring reoperation (16.4 percent). In our patient population, single-dose prophylactic intravenous antibiotic use has not been associated with a decreased risk of surgical-site infection, resulting in a greater number of reconstructive failures in patients undergoing prosthetic breast reconstruction. This risk is 4.74 times higher than in patients receiving postoperative prophylactic antibiotics. We have also noted a higher proportion of Gram-negative bacteria from the wound culture isolates of women requiring implant removal after the implementation of the Surgical Care Improvement Project guidelines (Fig. 2) . BacPlastic and Reconstructive Surgery • September 2012 terial isolates from women treated with postoperative antibiotics who required removal of the implant before the implementation of the Surgical Care Improvement Project guidelines were more likely to grow Staphylococcus (Fig. 1) . The use of postoperative prophylactic antibiotics in this group may have prevented Gram-negative infections and selected for more common and/or resistant Staphylococcus species, although we were unable to demonstrate this statistically.
We acknowledge several limitations of this study, with the foremost being its retrospective nature. Patients were not randomized and the duration of antibiotic therapy in the pre-Surgical Care Improvement Project group was not controlled for. Antibiotics were stopped after drain removal, which was performed when output was less than 30 ml/day. Although this was consistent, we did not record the mean duration of postoperative antibiotic use. Surgeons at our institution adopted the use of AlloDerm at approximately the same time; however, it was not used in all implantbased reconstructions. We did not record the rate of AlloDerm use for the entire study population, as the purpose of this study was not to examine risk associated with this product and it was used selectively and infrequently. Our group has been using this product for a number of years before the study and therefore we do not feel a learning curve effect was present. We are currently undertaking a prospective randomized study of the duration of antibiotic use at our institution and its impact on the development of surgical-site infection in patients undergoing prosthetic breast reconstruction. We will compare the efficacy of postoperative antibiotic prophylaxis in patients receiving the maximum allowed by current Surgical Care Improvement Project protocol (24 hours) to those receiving an experimental protocol (7 days).
The optimal duration of postoperative prophylactic antibiotic therapy has not been well established in the plastic surgery literature, and we believe the current recommendations are inadequate. We believe that a single dose of preoperative prophylactic antibiotics is not enough and has resulted in higher rates of surgical-site infection requiring reoperation in patients undergoing prosthetic breast reconstruction. 19 
Introduction
Most international health organisations would like to see an end to female genital mutilation. 1,2 Between 130 and 140 million women worldwide have undergone female genital mutilation in the past 10 years, including 92 million girls in Africa. Every year, an estimated 3 million girls are at risk of undergoing the procedure. 3 Female genital mutilation is widespread in Africa, but also occurs in immigrant communities in Europe and North America. It has medical, psychological, and psychosexual consequences, which have been described in detail. [4] [5] [6] [7] Nor should one forget the unacceptably high number of young girls who die as a result of lifethreatening infections such as tetanus or haemorrhage; in areas of Sudan where antibiotics are not available, a third of the girls undergoing female genital mutilation are estimated to die from infection. [8] [9] [10] Eff orts to end this procedure started decades ago, but require major social changes. Repairing the mutilation is an interim solution.
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Women with female genital mutilation rarely have access to reconstructive surgery to improve their lives. According to the WHO classifi cation, type III mutilation corresponds to the "narrowing of the vaginal orifi ce with creation of a covering seal by cutting and appositioning the labia minora and/or the labia majora, with or without excision of the clitoris (infi bulation)". 12 The WHO goes on to state that women who have undergone type III mutilation require defi bulation before delivery. Func tional improvements have been described after this defi bulation procedure, mainly in Somalian popula tions. [13] [14] [15] The surgical techniques described in the present Article were initially developed in the context of humanitarian medicine in Burkina Faso. In France, reconstructive surgery has been available on the French national health service since 2004. Surgery was initially off ered to women with pain sequelae, but has since been extended to women wishing to improve their sex lives or their physical appearance. In an earlier study, 15 which ran from 1992 to 2005, we were able to restore a visible clitoral mass in 394 (87%) of 453 patients, and 75% of women reported a genuine short-term improvement in clitoral function. 16 Most patients had undergone type II mutilation, that is, partial or total removal of the clitoris glans and the labia minora, with or without excision of the labia majora (excision).
However, patient satisfaction and outcomes were not measured over the long term. Here, we aim to assess both the immediate and long-term outcomes of reconstructive surgery for female genital mutilation to help women to improve their sex lives, recover their identity, and reduce pain. These were the objectives expressed by the women themselves, as described in our earlier publication 16 and subsequently corroborated in a survey.
17

Methods
Patients
Between 1998 and 2009, we prospectively included consecutive patients with female genital mutilation aged 18 years or older who had consulted a urological surgeon (PF) at St Germain Poissy Hospital, St Germain en Laye, France. Our study complied with all the French ethics requirements that were then in force, and was done according to French research guidelines. Approval from the Institutional Review Board (IRB) was not necessary since this study was done before it became mandatory in France in Feb 21, 2012. Patients were informed orally and in a written form about effi ciency and side-eff ects of surgical procedure. Our surgical ward receives patients with female genital mutilation who want to have their mutilation repaired. Most of the patients present themselves, but a few are referred. Our work was never publicised, and this study was done in a pragmatic setting, with no particular changes to our usual practices.
We used the WHO classifi cation 18 to prospectively include women with either type II or type III mutilation (infi bulation) with excision. We excluded patients with type III mutilation who had not undergone excision of the clitoris.
Procedures
All patients fi lled out a questionnaire at entry about their characteristics (age, country of origin, country of excision) and their preoperative clitoral pain and clitoral pleasure. We assessed the patients' expectations for pain and clitoral pleasure on 5-point scales (appendix). These scales pragmatically described the patients' sensations and had already been used elsewhere 16 but were not validated. For clitoral pleasure, for instance, patients could choose between: never (no sensation), minor sensation, pleasant without orgasm, restricted orgasm (orgasm with less intensity than wished), and regular orgasm ("normal" orgasm).
The surgeon (PF) did a standardised surgical procedure on all the patients. 18 The key surgical principle was to restore both clitoral anatomy and clitoral function 19 (fi gure; a full description of surgical procedure is available in the appendix). Under appropriate general anaesthesia via laryngeal mask; we fi rst created a circular "buttonhole" skin incision over the clitoral shaft stump. The skin covering the distal stump of the clitoris was resected sharply with scissors. The suspensory ligament was gradually transected close to the bone and as deeply as needed to allow suffi cient downward mobilisation of the clitoris to bring it to the glans' anatomical position. The dorsal region neurovascular bundle was preserved. A fi rst layer of suture was used to hold the extremity of the neoclitoral shaft in place to prevent retraction. Running or interrupted monocryl sutures were carefully placed inferiorly, passing from the residual fi brous layer surrounding the tunica to the vestibular mucosa and skin. Above the clitoris, the vestibular skin was closed with interrupted polyglactin stitches passing through the subcutaneous connective tissue on both sides and the periosteum in the middle. All the dissected spaces were infi ltrated with local anaesthetic (6 mL of ropivacaine 7·5 mg/mL). If necessary, the preliminary procedures done to uncover the clitoral stump consisted of defi bulation and removal of pseudocysts. See Online for appendix
Patients were discharged within 2 days of surgery. About two weeks after surgery, they were examined and asked to come back in a year's time. We informed them that postoperative pain would last for about 2 weeks and that the wound would take 2 months to heal (epithelialisation), at which point they would be able to resume sexual intercourse. At the 1-year visit, women were questioned about pain and functionality. We compared the 1-year group with the total group at inclusion to check for representativeness.
Statistical analysis
We prospectively entered the data in Stata 10, and did post-hoc analyses. We worked on the assumption that missing data were not a reason for exclusion, and analysed all the variables in a pragmatic way, according to available data. We provide the numerator for each variable. We used the χ² test to compare characteristics at inclusion. We took the year of attendance into account for all the preoperative criteria (Pearson test). We analysed the odd ratios and 95% CIs, and used logistic regression for the prognosis variables. Logistic was used for statistical analyses.
Role of the funding source
The sponsor of the study supported the data analysis and the English editing of the report, but had no role in the study design, data collection, data analysis, the writing of the report, or the decision to submit for publication. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. Data are n/N (%). *Pearson's χ² for clitoral pleasure before surgical procedure was 301·6109 Pr<0·0001, and for pain before surgical procedure 230·0051 Pr<0·0001. †Pearson's χ² for clitoral pleasure before surgical procedure was 62·4061 Pr<0·0001, and for pain before surgical procedure 33·6787 Pr=0·29. The proportion of patients with female genital mutilation who had never experienced clitoral pleasure rose according to the year of attendance (table 1) . Conversely, the proportion of patients who experienced pain diminished according to the year of attendance (table 1) . Younger patients reported less clitoral pleasure than did older ones, but no age-related diff erence was noted for pain (table 2) . Immediate complications after surgery (haema toma, suture failure, moderate fever) were noted in 155 (5·3%) of the patients, and 108 (3·7%) were briefl y re-admitted to hospital. Minor adverse events (pain, late wound healing, or wound secretions) were treated in outpatients with no readmission, but clear instructions and medications were given to patients at discharge. Minor adverse events with brief readmission were noted in 155 (5·3%) cases: pain (32), haematoma (97), suture failure (13) , and moderate fever (13) with a retention rate of 3·7% (108). At 1 year, no complications were recorded.
The fi gure shows some examples of aesthetic outcomes. We compared preoperative pain and clitoral pleasure with postoperative functionality at 1 year for 841 (97%) of the 866 women who attended the follow-up visit (table 3) . 129 (35%) of the 368 women who had never had an orgasm before the procedure started to experience restricted or regular orgasms. Half the women who presented with restricted orgasm before the procedure reported a regular orgasm after it (table 2) . Conversely, 12 (23%) of 53 patients who had regularly had orgasms before reported reduced orgasm afterwards. After reviewing non-evaluable patient case report forms, eight patients could be deemed as worsened. Thus, 20 patients in total were worsened for clitoral pleasure. After reconstruction, most patients reported an improvement, or at least no worsening, in pain and clitoral pleasure. Nine patients without pain before surgery had either discomfort (eight patients) or pain (one patient) at 1 year (table 2) .
Expectations from surgery were the recovery of identity (feeling whole and recovering personal autonomy by rejecting the physical mutilation imposed on them by their family group) 21 for 2933 (>99%) of the 2938 women, an improved sex life for 2378 (81%) women, and pain reduction for 847 (29%) women. Some expectations were linked to preoperative status ( Data are number of patients (%). We used pragmatic terms to defi ne pain (clitoral pain), discomfort (clitoral dicomfort), slight improvement (little improved), real improvement (very improved), restricted orgasm (restricted in intensity or frequency), regular orgasm (regular in intensity or frequency). *Non-evaluable (reviewed case report forms, results set out in the ms). †Improved. ‡Unchanged. §Worse. 1·40-3·43, p=0·007 ). We noted a signifi cant association in both our univariate (p=0·01) and multi variate analyses (p<0·0068) between overall outcome and year of attendance, with the most recently operated patients having better overall results. Some prognosis factors are set out in the appendix (infl uence of pre-operative symptoms, ie, pain and clitoral function, on surgical outcome). In summary, the patients' age at attendance was not predictive of clitoral recovery, nor was their country of excision. The functional outcome was closely correlated with expectations and preoperative symptoms (p<0·0001). Postoperative appearance was signifi cantly correlated with year of attendance (p=0·0007) and country of excision (p=0·0321). Age at attendance and age at excision were not predictive of aesthetic outcome.
Discussion
We have shown that reconstructive surgery after female genital mutilation reduces local pain and restores clitoral pleasure. These unmet needs are inadequately assessed, because sequelae from female genital mutilation are not easily disclosed by women. Our work was not publicised, however, in 2004 the issue gained publicity (newspapers, television) after the decision of the French health-care system to reimburse the surgical procedure, which might have aff ected the the increase in recruitment in 2004. The proportion of patients with female genital mutilation who had never had clitoral pleasure rose with year of attendance. This rise could be related to changing patient expectations: patients initially came to seek pain reduction, but subsequently were more concerned with enhancing their sex lives.
Another point is the increased reporting of sexual problems in the younger patients compared with the older age groups. This might be linked to general apprehension towards sexuality and lack of experience in some young people. Furthermore, the women in our study were confronted with a particular dilemma: how to cope with confl icting, culturally determined sexual ideologies. These issues in female genital mutilation have been described in two studies. 17, 22 A single surgeon (PF) did all 2938 procedures using the same technique in the same hospital. All consecutive patients were included, and few data of those patients followed up were missing.
The attendance in this female population with genital mutilation, which is in constant fl ux, has never been studied; so what constitutes a good or bad follow-up rate is unknown. Under these circumstances, we felt satisfi ed with 29% (861 of 2938) follow-up at 1 year, and we suspect that this follow-up rate refl ects the fact that many people may have remained in the Paris area. Nonetheless, the loss to follow-up is a major weakness of the study. It is always diffi cult to trace these patients, since they frequently move house and live in relative poverty.
Some studies have already been published on repair of female genital mutilation (panel);
13-15 however, they 14 The aim of reconstructive genital surgery after female genital mutilation should be to restore the normal anatomy as far as possible.
Another point of discussion is population selection. In 2009, Andro and colleagues 24 published a case-control study designed to measure the eff ect of female genital mutilation on the health of women living in France, including 714 excised women versus 2168 non-excised women. The authors noted that only 55% of participants with female genital mutilation were aware of the availability of surgical repair, 27% were interested in having it done, but only 3% had actually gone ahead with it.
The design of the present study had several limitations, notably the fact that it was an open before-and-after assessment and we had no long-term follow-up data for non-operated women, so causality could not be shown. Because we could not envisage a sham procedure, a comparative randomised study was not feasible. We designed our own rating scales for clitoral pleasure and pain, and these should doubtless have been more standardised and validated formally. Assessments were based on assumption, but as they were done both before and after the surgical procedure, each patient was her own control. Moreover, having the same investigator for all the procedures and assessments might have decreased some biases.
No scales currently exist specifi cally to assess pain and clitoral pleasure, and more studies in this area would be welcome. Some studies have explored the quality of the sex lives of patients with female genital mutilation. Using the validated female sexual function index (FSFI), Catania and colleagues 25 reported signifi cant diff erences between 57 infi bulated women and 57 controls in desire, arousal, orgasm, and satisfaction, with mean scores higher in the group of mutilated women than in the control group. But these fi ndings cannot lead to a clear conclusion since we believe that matching Italian women with African women constituted a major bias, and the FSFI has yet to be formally validated in a population of African women. Interestingly, in another group of patients, 25 the investigators noted that 86% of 137 women with female genital mutilation experienced orgasm (69% always). Even if these fi ndings are limited by important group recruitment biases, they could be compared with the 91% of women who experienced orgasm (only 9% always) noted in another group of 58 youngest women. At last, the fact that the sample essentially consisted of women with type III mutilation from Somalia (no cutting) well have explained the high orgasm rate.
In another study, 15 14 of 18 patients who had undergone defi bulation and who were assessed on the FSFI scale before and after, came from Somalia (not cut) and reported no improvement in orgasmic function. Even though we used a pragmatic scale, we consider that our procedure did indeed correct type II and type III (with cutting) mutilations, by giving the women a more functional clitoris. Further research should include a large case-control study (excised and non-excised) women with the administration of a validated questionnaire such as the FSFI, to fully understand and describe the subpopulation concerned by clitoral repair.
We had no data about the sexual partners women had before and after surgery. Sexual pleasure varies from one sexual partner to another, and this could therefore be another major limitation. The complexity of the sexual dysfunctions that can be associated with female genital mutilation underlines, for us, the need to systematically off er sexual therapy to patients. Furthermore, these women might have experienced suff ering and violence in many diff erent forms, which could result in post-traumatic stress disorder 4 -an aspect we are currently exploring. 564 patients in our series had undergone female genital mutilation in France, even though this practice has been strongly condemned in France. This exported tradition, hidden, and very much taboo, was fi rst brought to light some 20 years ago in several French cities. Although no specifi c legislation has ever been passed, since 1978, 25 prosecutions (French Penal Code Art222) of circumcisors or parents have taken place in France (the only country where this has happened). 26 From the public health point of view, these women were poor, and were only able to access surgical care because the French national health-care system bore the costs incurred. In most developed and all developing countries, reconstructive surgery is prohibitively expensive. Women have major unmet needs, and access to surgery is poor. In France, where most of the health expenses are reimbursed, there is only limited provision, because only a handful of surgeons have been trained in this technique, and fewer than ten off er this service in France. And yet, this surgery is rewarding for surgeons, in that we believe it genuinely helps women.
In developing countries, where the needs are greatest, reconstructive surgery is rarely accessible. Reconstructive surgery after female genital mutilation is not a priority in countries beset by public health emergencies. Informing international organisations that want to decrease female genital mutilation is key. They should help with reconstructive surgery.
Evidence-based health care should be the ultimate objective when developing a new surgical technique. Reconstructive surgery after female genital mutilation concerns very vulnerable populations, even in France. We focused our attention on the potential benefi ts for patients. We obtained safety data and proof of concept. We used our own prospective database, but more registries should be developed. We aim to conduct further investigations, such as comparative studies, and training programmes a multicentre evaluation programme should be implemented. The diff usion of a new technique takes time, and evaluation must be the fi rst step. [27] [28] [29] The assessment of the surgery is challenged by factors, such as learning curves, quality variations, and perception of equipoise. A large-scale programme is mandatory for assessing this technique before any diff usion. The unmet needs are great indeed. To help these mutilated women more eff ectively, we must not only defi ne the innovative surgery more clearly, but also consider time, communication channels, and the social system. Clitoral reconstruction after female genital mutilation is feasible. It can certainly improve women's pleasure and lessen their pain. It also allows mutilated women to recover their identity. Age at excision and age at attendance do not aff ect outcome. The operation must be followed by an adaptation period, and can only ever restore a potential. The extent to which this potential is realised will depend on each individual woman's life course and the many complex factors known to be related to sexuality. Reparative surgery can be a liberating experience, but many women have to strike a diffi cult balance between their desire for this liberation and the ordeal of calling family values and local traditions into question.
Clitoral reconstruction after female genital mutilation is feasible. It can improve women's pleasure and lessen their pain. It also allows mutilated women to recover their identity. Age at excision and age at attendance do not aff ect outcome. The operation must be followed by an adaptation period, and can only ever restore a potential. The extent to which this potential is realised will depend on each individual woman's life course and the many complex factors known to be related to sexuality. Reparative surgery can be a liberating experience, but many women have to strike a diffi cult balance between their desire for this liberation and the ordeal of calling family values and local traditions into question. Finally, although clitoral reconstruction is extremely important, we believe that women should be off ered a multidisciplinary care package, including sexual therapy, if this is acceptable to them.
Panel: Research in context
Systematic review
We searched PubMed with the keywords "female genital mutilation", "repair", "consequences", "sexuality", and "study", for all years and all languages, up to the end of December, 2011. Our objective was to select randomised trials and observational studies of more than 50 patients. We found 101 articles and selected the 17 highest level studies that are cited here. [3] [4] [5] [7] [8] [9] 11, [13] [14] [15] [16] 18, 19, [22] [23] [24] [25] This systematic review allowed us to describe both the immediate health complications and the long-term health risks. The frequency of clitoral pain is unknown, even though the reparative surgery was initially off ered to alleviate pain. With the exception of our own earlier study, all existing publications on repair of female genital mutilation concern type III mutilation without clitoral excision. The defi bulation technique they describe might improve women's sex lives by suppressing the dyspareunia that often accompanies this type of mutilation. Descriptions of the sex lives of excised women also mainly concern type III mutilation.
Interpretation
Our study of 2938 patients showed that among the 866 women who were followed up at 1 year, reconstructive surgery after female genital mutilation is eff ective. There was no mortality, only 5·3% morbidity and good feasibility. We operated mainly on women who had undergone type II excision. These patients reported pain reduction and an improvement in orgasmic function.
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Background:
The purpose of this study is twofold: (1) to stratify preoperative risk factors that predict successful free flap salvage and (2) to identify perioperative strategies that correlate with successful salvage. Methods: A retrospective chart review was performed on all free flaps performed from January of 2005 to April of 2011. The time until salvage was defined as the end of the initial procedure until the initiation of the salvage attempt. The primary endpoint, successful salvage, was defined as any flap that did not result in total loss. Results: A total of 2260 free flaps were reviewed, and 47 take-backs for delayed microvascular compromise were identified. Twenty-three of 47 flaps (49 percent) were salvaged. The mean time until take-back, presence of thrombophilia, and preoperative platelet counts were factors predictive of unsuccessful salvage. Preoperative platelet counts above 300 were associated with the lowest rates of salvage. Intraoperative maneuvers were examined, and surgeon experience (defined as Ͼ5 years in practice) was the only factor that was significant; however, intraoperative heparin anticoagulation and complete mechanical thrombectomy trended toward significance. The type of thrombolytic agent used was not found to result in a statistically significant difference. 
P
ostoperative microvascular compromise remains an infrequent yet devastating complication following free tissue transfer. Large series suggest that the rate of postoperative vascular thrombosis varies but may be at least 5 percent. [1] [2] [3] [4] [5] [6] Meanwhile, flap loss rates are now published to be less than 2 percent at many large microsurgery centers. 4, [7] [8] [9] The disparity in the rate of delayed vascular compromise and flap loss is dependent on the ability to successfully salvage a flap that has undergone postoperative venous or arterial thrombosis. Take-back procedures are both relatively uncommon and technically complex, making successful flap salvage a challenging endeavor. As a result, rates of flap salvage have been described to be 30 to 60 percent, and thus there is great room for improvement.
As approximately one-half of flaps are lost in salvage attempts, little is known about what separates these failures from the other half of takebacks that ultimately survive. To date, the literature has described early intervention as the only evidence-based strategy or factor that is associated with flap salvage. Otherwise, limited clinical data have come forth to supplant questions surrounding successful free flap salvage. Furthermore, intraoperative strategies have been relegated to level IV and V data when describing methods that may lead to flap salvage. The purpose of this study is twofold: (1) to stratify preoperative risk factors that predict the success of a take-back and (2) to identify evidence-based perioperative strategies that correlate with successful salvage.
PATIENTS AND METHODS
A retrospective review of records was performed on all patients undergoing free flap reconstruction at the Division of Plastic Surgery, University of Pennsylvania from January of 2005 to April of 2011. Free tissue transfer was examined in cases of breast, head/neck, and lower extremity reconstruction. Hospital records detailing the intraoperative and immediate postoperative course were used to identify patients who underwent a take-back for attempted flap salvage. A take-back was defined as any return to the operating room following the conclusion of the initial free flap procedure, departure from the operating room, and full reversal of general anesthesia.
The major inclusion criterion among takeback cases was delayed microvascular compromise; most often, this is a delayed venous or arterial thrombosis. After the patient leaves the operating room following the initial procedure, any vascular compromise is then considered "delayed." To clarify the inclusion criteria, the various take-backs were separated into distinct categories (Fig. 1) . Take-backs for general purposes such as hematoma, seroma, or infection were designated class 1 take-backs and were excluded from this study. Class 2 take-backs were those take-backs that were cases of delayed vascular compromise that underwent emergent reexploration. Class 2 takebacks were further subdivided into classes 2a, 2b, and 2c. Finally, class 3 take-backs were cases in which a necrotic flap underwent a planned débridement with no salvage maneuvers, and these cases were excluded from this study.
The primary endpoint, successful salvage, was defined as any flap that did not result in total flap loss. We specifically chose not to incorporate the often-described endpoint of "partial flap loss," as this is a rather ambiguous and imprecise variable Fig. 1 . The inclusion criteria and classification scheme.
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as far as retrospective studies are concerned. We did not feel this was an appropriate categorical variable, and for partial flap loss to be meaningful it would need to be a continuous variable (i.e., any portion of the flap débrided would have to be weighed and calculated as a percentage of the total flap). Likewise, we had no way of quantitating fat necrosis, to make it a proper continuous variable. When the primary endpoint of the study is flap loss, these are nearly meaningless endpoints unless they are properly quantitated. There is intersurgeon variability in how partial flap loss and fat necrosis are documented. Moreover, variables such as partial loss or fat necrosis can be ultimately attributed to potentially more significant variables such as perforator selection. Thus, one could argue that a case of fat necrosis would have occurred regardless of postoperative thrombosis. The true goal of this study is how to prevent total flap failure or, perhaps more specifically, how we can prevent recurrent thrombosis or the no-reflow phenomenon. These more nuanced variables such as fat necrosis or partial flap loss are too multifactorial or, at the very least, require more careful, prospective study.
Other data points of interest included patient demographics, comorbidities, presence of thrombophilia (confirmed by means of laboratory testing and/or prior history of blood clots), preoperative hematologic values, prior irradiation, surgeon experience, and time until salvage. The time until salvage was defined as the end of the initial procedure until the initiation of the salvage attempt. Intraoperative salvage maneuvers were examined, including the use of thrombolytics, anticoagulation, vein grafting, anastomotic site change, and mechanical thrombus removal.
Univariate statistical analyses included Fisher's exact test for categorical variables and the Mann-Whitney U test for continuous variables. In addition, a binary logistic regression model was used to test for multivariate significance. All tests were two-sided, and a value of p Յ 0.05 was used to determine statistical significance. Statistical analysis was performed using SPSS for Windows version 18.0 (SPSS, Inc., Chicago, Ill.).
Flap Monitoring
All flaps were monitored by a standardized protocol, and this did not vary between the surgeons. Flap monitoring was performed by means of conventional clinical indicators (i.e., color, temperature change, capillary refill, turgor) and hand-held arterial Doppler ultrasonography. Buried flaps, or those without a skin paddle, were monitored by means of an implantable Doppler system. Doppler checks were performed by trained nursing staff every 15 minutes for the first hour, then every hour for the next 48 hours, and then every 4 hours until the time of discharge, which usually occurred on postoperative day 4.
Surgical Technique
On changes in Doppler signaling and/or clinical indicators suggestive of thrombosis, flaps are returned to the operating room immediately (typically within 1 hour). There is intersurgeon variability regarding perioperative protocol and intraoperative salvage maneuvers. Surgeons often administer intravenous heparin (typically 5000 units) following elevation of the flap. The anastomosis is routinely taken down and a mechanical thrombectomy is performed (with the goal of removing the thrombus in its entirety). The thrombosed vessel segment is cut back until, ideally, pristine intima is reached. Thrombolytic agents are used based on the availability of a particular agent, surgeon preference, type of thrombus, and appearance of the flap following thrombectomy. Typically, 250,000 units of thrombolytic agent is infused with a 25-gauge butterfly needle while the flap is occluded from the systemic circulation. 13 Anastomotic site change is typically not performed; however, this is done when the recipient vessels are no longer judged to be viable. Similarly, vein grafting is not routinely performed unless a length discrepancy results following the cut-back of the vessel.
RESULTS
A total of 2260 flaps were examined in the study period from January of 2005 to April of 2011. Forty-seven flaps met the inclusion criteria as class 2 cases returning to the operating room for an emergent take-back following delayed microvascular compromise (Fig. 1) . Twenty-three of 47 flaps (49 percent) were salvaged. The rates of salvage for arterial and venous compromise were 52 and 46 percent, respectively. Figure 2 is a bar graph demonstrating the time until take-back for the 47 flaps, and Table 1 lists the corresponding salvage rates for each time period. The first 24 hours had the highest frequency of take-backs. Postoperative days 2, 3, and 4 had a relatively equal distribution in both the number and type of take-backs. Figure 3 describes the salVolume 130, Number 3 • Free Flap Take-Back vage rate in the first 48 hours versus the 49-to 96-hour period versus greater than 96-hour time period. No flap beyond postoperative day 4 (Ͼ96 hours) was salvaged. When examining the "allflaps group" and those with "arterial compromise," rates of salvage declined progressively further into the postoperative time period. This decline in salvage rate was statistically significant for the all-flaps group (p ϭ 0.005) and the arterial compromise group (p ϭ 0.018). The rate of salvage in the "venous compromise group" improved before subsequently declining. However, this was not significant (p ϭ 0.06).
Time until Take-Back and Salvage Rate
Risk Factors
Preoperative factors were then examined for those flaps that were salvaged compared with those that ultimately failed. After univariate analysis, the mean time until take-back, presence of Plastic and Reconstructive Surgery • September 2012 thrombophilia, and mean preoperative platelet counts were significant factors predictive of unsuccessful salvage (Table 2) . A multivariate binary logistic regression model examining mean time until take-back, thrombophilia, and preoperative platelet counts demonstrated platelet counts to remain significant (p ϭ 0.05) ( Table 3) .
Class 2b (Intraoperative Analysis)
In an attempt to determine effective intraoperative maneuvers for cases of delayed vascular thrombosis, a more homogenous subgroup (class 2b) was created for analysis (Fig. 1) . As a class 2b subgroup, the remaining 36 flaps that underwent salvage maneuvers were examined for both preoperative and intraoperative factors that could potentially predict success. After univariate analysis of this subgroup, preoperative platelet values remained significant (Table 4 ). In examining intraoperative salvage data, surgeon experience (defined as Ͼ5 years in practice) was significant. Intraoperative heparin anticoagulation (p ϭ 0.06) and complete mechanical removal of a thrombus (p ϭ 0.06) trended toward significance (Table 5) . Figure 4 contrasts preoperative platelet values for flaps that were salvaged versus those that were not salvaged. The values are plotted separately for venous and arterial compromise. The overall percentage of flap salvage was calculated for arterial and venous compromise combined. Patients with preoperative values less than or equal to 200 experienced the highest levels of salvage success (71 percent), whereas those patients with preoperative values approaching or beyond 300 experienced the lowest rates of salvage. Figure 4 also suggests that those who experience venous thrombosis tend to have higher preoperative platelet values than those who experience arterial thrombosis.
Platelet Values
DISCUSSION
This study represents one of the largest takeback series in the published literature. The overall flap salvage rate was 49 percent. The rates of salvage for arterial and venous compromise were 52 and 46 percent, respectively. It is difficult to compare our salvage rate to the few other series on take-backs because we chose to exclusively examine microvascular compromise rather than include general complications (e.g., hematoma). In exclusively examining thrombosis, Vijan and Tran similarly published a 55 percent salvage rate in 18 breast reconstruction take-backs. 
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The mean time until take-back was significantly different between those flaps that failed and those flaps that were salvageable. The mean time until take-back was nearly twice as long in the failure group in comparison with the salvage group (35.3 and 70.1 hours, respectively; p ϭ 0.02). We chose to define time until take-back as the number of hours from the end of the initial procedure to the start of the take-back. This was chosen rather than attempting to examine the time from thrombosis to take-back. Even with meticulous documentation and vigilant flap observation, these values are neither reliably accurate nor precise enough for scientific scrutiny. Operating room start and end times allowed for more definitive values while still providing insight and utility. Furthermore, our intention was to provide practical data for use by other microsurgeons to predict the likelihood of flap salvage. In the clinical setting, there often exists the same frustration and ambiguity regarding the exact time at which thrombosis occurred. By examining these data, surgeons can more objectively identify the time from the end of the initial operation until the start of the salvage attempt.
Interestingly, it seems that flaps undergoing a take-back on later postoperative days have lower rates of salvage even when it is thought that the vascular compromise was readily detected (Table  1 and Fig. 3) . In another large series of pedicle thromboses, Panchapakesan et al. noted that despite seemingly timely intervention for all cases of vascular compromise, the time from surgery to salvage was a significant factor. 12 There are two possible explanations for this: (1) thrombosis most often occurs early and these late salvage attempts are nearly all cases of delayed detection; and (2) late thrombosis is inherently more devastating or difficult to correct even with a prompt return to the operating room. Perhaps both of the aforementioned explanations contribute to low salvage rates in very late take-backs. We were unable to salvage any flaps beyond postoperative day 4, and Kroll et al. could not salvage flaps beyond postoperative day 3. 
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In plotting the take-back time and success rates for venous versus arterial compromise, some interesting observations were made. First, our results are in accordance with those of Kroll et al., who suggested that most thrombi occur within the first 24 hours. Second, arterial compromise appeared to be correctable at much higher rates in comparison with venous compromise, particularly in the first 48 hours (77 percent arterial salvage rate versus 50 percent venous salvage rate). It has been speculated that this is in part because of the difficulty in detecting loss of venous flow with routine Doppler systems. The complete loss of the Doppler signal is easier to recognize rather than the monophasic, "water-hammer" signal unique to loss of venous flow. Furthermore, animal studies have demonstrated that skin change may be an unreliable and untimely clinical detector for the severity of venous congestion. 15 It seems, however, that any potential delay in detection with venous compromise cannot fully explain the large discrepancy in salvage rates. Perhaps the interstitial edema and physiologic microvascular change resulting from severe venous congestion is a far less reversible state than a temporary loss of arterial inflow. As a result, the damage Volume 130, Number 3 • Free Flap Take-Back incurred from venous failure may be more swift and definite.
In examining Table 1 , the salvage rates decline when examining arterial loss and all flaps combined; however, this linear decline is not observed with venous compromise. When finely dichotomizing these data by individual day and type of vascular compromise, all statistical significance is lost (Table 1) . We then constructed Figure 3 , which groups flaps by 48-hour time intervals rather than by 24-hour time periods. Figure 3 suggests that the salvage rate of venous compromise actually improved in the later 45-to 96-hour postoperative period. There is likely a multifactorial explanation. First, this could simply be a matter of inadequate study power, as it should be emphasized that this observation was not statistically significant. It has, however, been speculated that very early venous thrombosis is a more ominous sign in comparison with later venous thrombosis. This finding of improved venous compromise salvage in the 45-to 96-hour time period can also be an artifact of our choice to use time until take-back (as opposed to time from thrombosis to take-back) and the fact that venous thromboses tend to occur later than arterial thromboses. Thus, the sharp decline in arterial salvage rate could be explained by the fact that most arterial thromboses occur in the first 24 hours and that later take-backs in the 45-to 96-hour time period were likely more a matter of delayed intervention, leading to a sharp decline for arterial thrombosis salvage.
In addition to improving statistical analysis, Figure 3 represents critical changes in postoperative monitoring. After 48 hours postoperatively, flap monitoring becomes every-4-hour Doppler checks, and after 96 hours patients are most often discharged. At each of these time intervals in Figure 3 , the salvage rate generally declines. Clearly, there are multiple reasons why salvage rates decline (particularly in how we defined time until take-back); however, one may reason that the decline in salvage rate could be strongly associated with these essential changes in flap monitoring. With our current flap monitoring protocol, flaps only undergo Doppler checks every 4 hours beyond 48 hours postoperatively, but clearly issues can still arise in this time period. In fact, there was a relatively equal distribution of take-backs on days 2, 3, and 4. As seen in Figure 1 , at least eight flaps were necrotic by the time the flap was elevated. In addition, authors who have attempted to monitor Plastic and Reconstructive Surgery • September 2012 the time from thrombosis to salvage have stressed the seemingly small time window separating success from failure. In the study by Vijan and Tran, 14 the mean time of successful salvage and failure was 127 minutes and 192 minutes, respectively (the latest flap they were able to salvage was 188 minutes after detection of thrombosis). Along with the aforementioned study by Vijan and Tran, our data could insinuate that Doppler checks every 4 hours are insufficient, and now with Doppler monitoring, our time interval for monitoring does not exceed every 2 hours at any point prior to discharge. Yet, checks every 1 to 2 hours for over 96 hours would be an arduous task for the floor nurses, thus making the call to other methods of monitoring. While our data are not conclusive, they should be the impetus for questioning the efficacy of the standard Doppler monitoring protocol and perhaps the previously underestimated role of constant monitoring techniques.
Systems more sophisticated than hand-held Doppler probes have been described in the literature, including near-infrared spectroscopy, microdialysis, and laser Doppler flowmetry. There has been conflicting evidence as to whether implantable Doppler probes improve the salvage rate. 11, 16, 17 A recent study by Lin et al. claims an improved salvage rate from 57.7 percent to 93.75 percent with tissue oximetry monitoring. 18 Perhaps utilization of these more sensitive measures truly leads to higher rates of salvage, as animal studies have demonstrated that changes at the microvascular level begin as early as 60 minutes after ischemia. 19 Even still, our data indicate that intrinsic factors of the patient may be at least as important, regardless of the timing of the take-back. Accordingly, in moving beyond the long-established and intuitive matter regarding the timing of the takeback, our data are the first to provide level III evidence to establish that it is also dependent on who is undergoing salvage and how it is done. Patients with a known thrombophilia were poor candidates for take-back procedures. Seven of eight patients with a thrombophilia ultimately failed the salvage attempt. It is also worth noting that the one patient whose flap was salvaged had the "softest" history of hypercoagulability and no laboratory confirmation of a blood disorder. Patients with a known thrombophilia may not be contraindicated for free tissue transfer, but they should be strongly counseled as to the grim prognosis of postoperative thrombosis.
Although named hypercoagulable states (e.g., protein C deficiency) are difficult to detect, our data suggest that preoperative platelet values may be a simple and reliable routine laboratory value that could predict the ability to salvage a flap. Preoperative platelet values were significantly higher in those who underwent a failed salvage attempt (Fig. 4) . Interestingly, this may also be further evidence to suggest that platelets play a critical role in the physiology of thrombosis, ischemia, and reperfusion injury.
It has been long established that platelets can be the source of microemboli that travel downstream from an arterial anastomosis to disrupt capillary perfusion. 20 Rather than just the physical effects of platelets on the microcirculation, platelets appear to cause deleterious effects on the microvasculature by chemical means as well. Clinical and laboratory studies from the cardiovascular literature have elucidated the critical role that platelets play in myocardial ischemia-perfusion injury. These studies on myocardium have found that platelets cause damage to microvasculature in ways including but not limited to (1) releasing vasoconstrictive substances (e.g., thromboxane A2, serotonin), (2) potentiating the inflammatory cascade [e.g., release interleukin-1␤, RANTES (regulated upon activation, normal T-cell expressed, and secreted), or CD40 ligand], (3) activating and adhering to leukocytes, and (4) releasing oxygen free radicals and thrombin. 21 Our data further suggest that platelets play a role in tissue injury following thrombosis and, furthermore, that platelets may be a worthwhile therapeutic target during flap salvage. An animal study by Peter et al. demonstrated that the pretreatment of aspirin resulted in decreased thrombus formation at the anastomosis and increased downstream capillary perfusion. By reducing thromboxane A2 formation (a platelet aggregator and vasoconstrictor), low-dose aspirin has demonstrated potential benefits in the setting of flap salvage. 22, 23 Even still, aspirin has a limited ability to modulate platelet activity; perhaps adenosine diphosphate receptor antagonists (clopidogrel or faster acting cangrelor) may be more efficacious. 21 Previous laboratory studies have compared the effects of fish oil versus systemic heparin on platelet microemboli. Heparin reduced the number of emboli but did not improve capillary perfusion. Conversely, neither fish oil nor ridogrel reduced the number of platelet emboli, but both improved capillary perfusion. Their conclusion, which seems to have since been validated by the aforementioned cardiovascular literature, is that platelets also play a substantial biochemical role in decreased capillary perfusion. 22, 24 In our series, Volume 130, Number 3 • Free Flap Take-Back intraoperative heparin use was associated with improved outcomes, perhaps by decreasing the physical presence of platelet microemboli in the microcirculation. Evidence of physical emboli in the microcirculation seems to be emphasized with the successful infusion of thrombolytics. During a successful infusion, the real-time change in Doppler signal and decrease in syringe pressure (microvascular resistance) suggest the clearance of a physical obstruction. 13 In an attempt to identify efficacious intraoperative maneuvers for cases of delayed microvascular thrombosis, the class 2b subgroup analysis was performed. Including class 2a or 2c patients would have precluded a reasonable analysis of intraoperative maneuvers. Consequently, this created a more homogenous subgroup of delayed microvascular thromboses, all of which appeared to be viable after flap elevation and likely returned to the operating room in a timelier manner than the class 2c counterparts (notice that the time until take-back is no longer significant in the class 2b subgroup analysis; Table 4 ). In this subgroup analysis, surgeon experience was highly significant. Given the infrequency of take-backs, particularly those that are the result of a thrombosis, many years of high-volume microsurgery are required to obtain any reasonable level of experience with this scenario. It should also be noted, however, that the most senior surgeon has the highest volume of breast microsurgery, and this has been demonstrated to result in higher rates of salvage than head/neck or lower extremity cases. 25 It should also be noted that this most senior surgeon most liberally uses aspirin in the perioperative period.
Given the paucity of evidence-based data for successful salvage, expert opinion and experience are seemingly paramount to success, along with technical proficiency. The importance of the technical expertise is demonstrated, as the mechanical removal of a thrombus, in its entirety, also trended strongly toward significance (p ϭ 0.06). Understandably, this is associated with success, as residual clot may be the nidus for another large thrombosis or potentially the source of microemboli.
Unfortunately, we were unable to glean data on the efficacy of thrombolytics for salvage. These clinical data will continue to be difficult to obtain because of study power and, moreover, the fact that thrombolytics are preferentially used in more difficult cases of salvage. 26, 27 Even more difficult to demonstrate is a difference in efficacy between streptokinase (which enhances plasminogen to plasmin conversion), urokinase (which directly converts plasminogen), or tissue plasminogen activator (which directly converts plasminogen). Nonetheless, we feel strongly about their role in salvage, particularly for recalcitrant cases of ischemia/congestion, and their effects are often readily apparent intraoperatively. The same can be said for other intraoperative factors such as anastomotic site change, use of a Fogarty catheter, or vein grafting. The low power and selection bias makes their efficacy difficult to determine.
One of the weaknesses of this study is the heterogeneity of the flap type and patient population. This is the constant dilemma of clinical researchstudy population homogeneity versus study power. With over 2000 free flaps, there are still likely some components of our study that our underpowered. Removing all nonbreast cases would likely make the entire study underpowered. To be sure, we did not find nonbreast cases to be a risk factor in our patient population, as we examined breast versus nonbreast cases and breast versus head/neck versus lower extremity cases. Because this is not a risk factor on univariate analysis, there is no compelling case from a statistical standpoint to remove the head/neck and lower extremity patients. Perhaps, as our data suggest, these flaps truly are salvaged at equivalent rates. At the very least, it is not a risk factor in our patient population; therefore, we do not feel compelled to remove these patients from our study. Many of the factors we identified (e.g., surgeon experience or thrombophilia) are likely relevant regardless of flap type or site of reconstruction.
CONCLUSIONS
To achieve the highest levels of success in microsurgery, it is necessary to improve rates of salvage following delayed microvascular compromise. There is evidence to suggest that there are preoperative factors that are predictive of flap salvage success, including the time until take-back, preoperative platelet values, and the presence of thrombophilia. Shorter time to take-back and surgeon experience may improve salvage, and intraoperative heparin anticoagulation and complete mechanical removal of the thrombus demonstrate preliminary evidence as effective intraoperative strategies. A s the name suggests, evidence-based medicine is about finding evidence and using that evidence to make clinical decisions. A cornerstone of evidence-based medicine is the hierarchical system of classifying evidence. This hierarchy is known as the levels of evidence. Physicians are encouraged to find the highest level of evidence to answer clinical questions. Several articles published in plastic surgery journals concerning evidence-based medicine topics have touched on this subject. [1] [2] [3] [4] [5] [6] Specifically, previous articles have discussed the lack of higher level evidence in Plastic and Reconstructive Surgery and the need to improve the evidence published in the Journal. Before that can be accomplished, it is important to understand the history behind the levels and how they should be interpreted. This article focuses on the origin of levels of evidence, their relevance to the evidence-based medicine movement, and the implications for the field of plastic surgery and the everyday practice of plastic surgery.
HISTORY OF LEVELS OF EVIDENCE
The levels of evidence were originally described in a report by the Canadian Task Force on the Periodic Health Examination in 1979. 7 The report's purpose was to develop recommendations on the periodic health examination and base those recommendations on evidence in the medical literature. The authors developed a system of rating evidence (Table 1) when determining the effectiveness of a particular intervention. The evidence was taken into account when grading recommendations. For example, a grade A recommendation was given if there was good evidence to support a recommendation that a condition be included in the periodic health examination. The levels of evidence were further described and expanded by Sackett 8 in an article on levels of evidence for antithrombotic agents in 1989 (Table 2). Both systems place randomized controlled trials at the highest level and case series or expert opinions at the lowest level. The hierarchies rank studies according to the probability of bias. Randomized controlled trials are given the highest level because they are designed to be unbiased and have less risk of systematic errors. For example, by randomly allocating subjects to two or more treatment groups, these types of studies also randomize confounding factors that may bias results. A case series or expert opinion is often biased by the author's experience or opinions, and there is no control of confounding factors.
MODIFICATION OF LEVELS
Since the introduction of levels of evidence, several other organizations and journals have adopted variations of the classification system. Diverse specialties are often asking different questions, and it was recognized that the type and level of evidence needed to be modified accordingly. Research questions are divided into the following categories: treatment, prognosis, diagnosis, and economic/decision analysis. For example, Table 3 shows the levels of evidence developed by the American Society of Plastic Surgeons for prognosis 9 and Table 4 shows the levels developed by the Centre for Evidence-Based Medicine for treatment. 10 The two tables highlight the types of studies that are appropriate for the question (prognosis versus treatment) and how quality of data is taken into account when assigning a level. For example, ran-domized controlled trials are not appropriate when looking at the prognosis of a disease. The question in this instance is, "What will happen if we do nothing at all?" Because a prognosis question does not involve comparing treatments, the highest evidence would come from a cohort study or a systematic review of cohort studies. The levels of evidence also take into account the quality of the data. For example, in the chart from the Centre for Evidence-Based Medicine, a poorly designed randomized controlled trial has the same level of evidence as a cohort study.
A grading system that provides strength of recommendations based on evidence has also changed over time. Table 5 shows the Grade Practice Recommendations developed by the American Society of Plastic Surgeons. The grading system provides an important component in evidence-based medicine and assists in clinical decision making. For example, a strong recommendation is given when there is level I evidence and consistent evidence from level II, III, and IV studies available. The grading system does not degrade lower level evidence when deciding recommendations if the results are consistent.
INTERPRETATION OF LEVELS
Many journals assign a level to the articles they publish, and authors often assign a level when submitting an abstract to conference proceedings. This allows the reader to know the level of evidence of the research, but the designated level of evidence does always guarantee the quality of the research. It is important that readers not assume that level I evidence is always the best choice or appropriate for the research question. This concept will be very important for all of us to understand as we evolve into the field of evidence-based medicine in plastic surgery. By design, our designated surgical specialty will always have important articles that may have a lower level of evidence because of the level of innovation and technique articles that are needed to move our surgical specialty forward.
Although randomized controlled trials are often assigned the highest level of evidence, not all randomized controlled trials are conducted properly, and the results should be scrutinized carefully. Sackett 8 stressed the importance of estimating types of errors and the power of studies when All-or-none study 2a
Systematic review (with homogeneity) of cohort studies 2b
Individual cohort study, including low-quality RCTs (e.g., Ͻ80% follow-up) 2c
"Outcomes" research; ecological studies 3a
Systematic review (with homogeneity) of case-control studies 3b
Individual case-control study 4 Case series (and poor quality cohort and case-control study) 5
Expert opinion without explicit critical appraisal or based on physiology, bench research, or "first principles"
RCT, randomized controlled trial. *From the Centre for Evidence-Based Medicine (Web site). Available at: http://www.cebm.net. Accessed December 17, 2010.
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interpreting results from randomized controlled trials. For example, a poorly conducted randomized controlled trial may report a negative result because of low power when in fact a real difference exists between treatment groups. Scales such as the Jadad scale have been developed to judge the quality of randomized controlled trials. 11 Although physicians may not have the time or inclination to use a scale to assess quality, there are some basic items that should be taken into account. Items used for assessing randomized controlled trials include randomization, blinding, a description of the randomization and blinding process, a description of the number of subjects who withdrew or dropped out of the study, the confidence intervals around study estimates, and a description of the power analysis. For example, Bhandari et al. 12 published an article assessing the quality of surgical randomized controlled trials. The authors evaluated the quality of randomized controlled trials reported in the Journal of Bone and Joint Surgery from 1988 to 2000. Articles with a score of greater than 75 percent were deemed high quality, and 60 percent of the articles had a score less than 75 percent. The authors identified 72 randomized controlled trials during this time period, and the mean score was 68 percent. The main reason for the low-quality score was lack of appropriate randomization, blinding, and a description of patient exclusion criteria. Another article found the same quality score of articles in the Journal of Bone and Joint Surgery with a level 1 rating compared with level 2. 13 Therefore, one should not assume that level 1 studies are of higher quality than level 2 studies.
A resource for surgeons to use when appraising levels of evidence are the users' guides pub- 
PLASTIC SURGERY AND EVIDENCE-BASED MEDICINE
The field of plastic surgery has been slow to adopt evidence-based medicine. This was demonstrated in an article examining the level of evidence of articles published in Plastic and Reconstructive Surgery. 19 The authors assigned levels of evidence to articles published in Plastic and Reconstructive Surgery over a 20-year period. The majority of studies (93 percent in 1983) were level IV or V, which denotes case series and case reports. Although the results were disappointing, there was some improvement over time. By 2003, there were more level I studies (1.5 percent) and fewer level IV and V studies (87 percent). A recent analysis looked at the number of level I studies in five different plastic surgery journals from 1978 to 2009. The authors defined level I studies as randomized controlled trials and meta-analyses and restricted their search to these studies. The number of level I studies increased from one in 1978 to 32 by 2009. 20 From these results, we see that the field of plastic surgery is improving the level of evidence but still has a long way to go, especially in improving the quality of studies published. For example, approximately one-third of the studies involved double blinding, but the majority did not randomize subjects, describe the randomization process, or perform a power analysis. Power analysis is another area of concern in plastic surgery. Volume 128, Number 1 • Levels of Evidence
